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Primary plasmacytomaAbstract
Plasmacytomas could involve any organ, and at timesmight pose a diagnostic challenge when the
site of involvement is unusual, or if the presentation is similar to other diseases.We describe a 48-
year-old man presenting with worsening shortness of breath and chest discomfort with radiologic
evidence of mediastinal enlargement, mimicking a lymphoma with mediastinal involvement. An
excisional biopsy of amediastinal lymph node showed a plasma-cell infiltrate strongly positive for
CD138, with a flow-cytometry analysis showing a population of lambda-restricted neoplastic
plasma cells. He failed to respond to 50 Gy involved-field radiotherapy, but achieved a partial
response to combination chemotherapy. He underwent high-dose chemotherapy with melphalan
(200 mg/m2) followed by lenalidomide maintenance, and is in complete remission 18 months
postautografting. This case illustrates a unique and rare presentation of primary lymph-node
plasmacytomas involving the mediastinum potentially mistaken as lymphoid malignancy.
Clinicians should be aware of the plasma-cell origin of the mediastinal neoplastic process.
 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).A plasmacytoma represents a neoplastic process
comprised of clonal plasma cells [1]. Plasmacytomas can
present as an isolated disease process, or might represent
the first manifestation of multiple myeloma, or could signal
evidence of disease relapse/progression after the treatment
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might pose a diagnostic challenge when the site of involve-
ment is unusual or if the presentation is similar to other dis-
eases [2]. We describe a case of multiple extramedullary
plasmacytomas presenting as a symptomatic mediastinal
mass mimicking a lymphoma with mediastinal involvement.
This case illustrates diagnostic challenges that clinicians
might face in daily practice.
Case report
A 48-year-old man presented with worsening shortness of
breath and chest discomfort. He had no constitutional
symptoms. A complete blood count showed mild anemia
(hemoglobin: 11.2 g/dL) and reactive thrombocytosis
(platelets: 616,000/lL). The serum lactate-dehydrogenase
level was 152 (normal range: 94–250 U/L). The serum
beta-2 microglobulin was 1.65 (normal range: 0.002–2.70
lg/mL). The serum calcium level was 9.7 (normal range:
8.4–10.6 mg/dL). A chest X-ray showed mediastinal
enlargement. A positron emission tomography with com-
puted tomography demonstrated diffuse hypermetabolic
mediastinal adenopathy involving the paratracheal, precari-
nal, and subcarinal areas. An aortopulmonary-window
lymph node measured 5.6  4.5 cm in size with a maximum
standardized uptake value (SUV) of 14. There were two
additional hypermetabolic skeletal lesions: a 0.9 cm lytic
lesion in the posterior superior iliac bone (maximum SUV
4.7) and another 0.9 cm lytic lesion on the right side of
the sternum (maximum SUV 8.2). A bone-marrow aspirate
and biopsy showed normocellular marrow with maturing tri-
lineage hematopoiesis and slightly hyperplastic megakary-
opoiesis without evidence of monoclonal plasma cells. A
serum protein electrophoresis with immunofixation identi-
fied an immunoglobulin-G-lambda monoclonal gammopathy
(monoclonal spike [M-spike] 2.1 g/dL), as well as a free
lambda protein band. The serum-lambda-free light chain
was elevated at 1613.74 (normal range: 5.71–26.30 mg/L)
with a serum-kappa-free light chain of 4.61 (normal range:
3.30–19.40 mg/L). A bone survey revealed a 1.3 cm lucent
lesion overlying the parietal bone. An excisional biopsy of
a mediastinal lymph node showed a plasma-cell infiltrate
(Figure 1A), which was strongly positive for CD138
(Figure 1B) and negative for CD3, CD20, PAX-5, bcl-1 (cyclin
D1), and human herpes virus-8. In-situ hybridization for
EBER (EBV) was negative. A flow cytometric analysis showed
a population of lambda-restricted neoplastic plasma cells
positive for CD38, CD138, CD117, CD56, and CD16.
The patient received involved-field radiotherapy to the
mediastinal lesions at a cumulative dose of 50 Gy (in 25
fractions) without significant evidence of response. He then
received two cycles of infusional chemotherapy with
bortezomib, thalidomide, dexamethasone, cisplatin, dox-
orubicin, cyclophosphamide, and etoposide (VTD-PACE). A
repeat positron emission tomography with computed
tomography showed no metabolic activity in the medi-
astinum. Subsequently, a third cycle of VTD-PACE was
administered. Prior to autografting, his serum M-spike
was 0.4 g/dL, and the serum-free lambda chain was
16.45 mg/L, consistent with a partial response. There were
fewer than 5% plasma cells in the bone marrow. He thenreceived high-dose melphalan at 200 mg/m [2], followed
by autologous hematopoietic cell transplantation (HCT).
At 3 months after transplantation, the serum M-spike
remained stable at 0.4 g/dL. A posttransplant maintenance
therapy with lenalidomide was prescribed. Six months after
autografting, he developed axillary and infraclavicular fluo-
rodeoxyglucose avid lesions (maximum SUV 7.8), as well as
subcutaneous lesions (maximum SUV 7.9). A needle biopsy
of the left axillary node and subcutaneous lesions demon-
strated no evidence of plasmacytoma, but cultures grew
methicillin-resistant Staphylococcus aureus. The patient
was treated with sulfamethoxazole/trimethoprim, with
complete resolution of symptoms. He is in complete remis-
sion with an undetectable serum M-spike and negative
immunofixation at 18 months postautologous HCT.
Discussion
This case illustrates a rare presentation of a plasmacytoma
predominantly involving the mediastinal lymph nodes with
significant clinical symptomatology mimicking a mediastinal
lymphoma. An extensive review of the literature (published
in the English language) identified a limited number of cases
with mediastinal involvement by extramedullary plasmacy-
tomas [3–5]. Plasmacytomas primarily involving lymph
nodes are even rarer [6,7]. Primary lymph-node plasmacy-
tomas are estimated to represent only 2% of all extramedul-
lary plasmacytomas [6]. Many primary lymph-node
plasmacytomas are mostly described in case-reports [6,8],
with a minority of cases described as arising in plasma-
cell-type Castleman’s disease [7]. An extramedullary plas-
macytoma in the mediastinum can also present with
superior-vena-cava syndrome by its mediastinal location
and possibly compressive nature, although deemed rare [9].
Menke et al. [6] reviewed 26 cases of primary lymph-
node plasmacytomas reported in the literature that were
not associated with Castleman’s disease. There was a male
predominance, and the average age of affected patients
was 56 (range: 10–72 years) [6]. The most common presen-
tation was neck swelling due to a localized mass. Otherwise,
those plasmacytomas were asymptomatic, contrary to our
case. The average size of the excised lymph node was 4.6
(range: 2–10 cm) [6]. In the review of additional 25
lymph-node plasmacytomas from Mayo Clinic, Menke et al.
[6] described the distribution of these lymph nodes as fol-
lows: cervical 56%, abdominal 16%, mediastinal 12%, axillary
8%, and inguinal 8%. Only very few cases had disseminated
lymphadenopathy on both sides of the diaphragm, and by
definition there were no bone-marrow plasma-cell involve-
ment, as in our case. Immunophenotypically, these lymph-
node plasmacytomas may have distinct profiles compared
with other extramedullary plasmacytomas or myeloma.
They have increased CD30 expression and decreased MB2
(B-cell antigen) and CD45RO expression [6]. These plasma-
cytomas were frequently associated with serum monoclonal
gammopathy (43%) of the immunoglobulin-G subtype [6].
Those patients who had a localized disease were treated
with surgical excision alone or radiation therapy, and had
reportedly excellent outcomes [6]. They described one
case with a localized 5 cm unresectable mediastinal
plasmacytoma treated with 50 Gy of radiation. There was
Figure 1 (A) The photomicrograph of mediastinal lymph node by hematoxylin-and-eosin stain shows extensive plasma cell
infiltrate replacing the underlying lymph node structure. The image insert in the right lower corner demonstrates a higher
magnification view of medium-size atypical plasma cells with condensed chromatin, conspicuous small nucleoli, round to irregular
nuclear contours, eccentric nuclei, and moderate amounts of amphophilic cytoplasm. (B) Immunohistochemical staining with CD138
antibody demonstrates effacement of lymph node by numerous plasma cells consistent with a plasmacytoma.
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persisted on subsequent imaging [6]. Patients could develop
a disseminated disease after failing surgical or radiation
therapy. Disseminated lymph-node plasmacytomas were
mostly treated with combination chemotherapy akin to
treatment of multiple myeloma. The use of high-dose ther-
apy followed by autologous HCT has not been specifically
reported in lymph-node plasmacytomas, although it is con-
ceivable that patients receiving systemic chemotherapy
may have been offered autologous HCT as consolidation.
Patients with a disseminated disease did not attain long dis-
ease control due to disease spreading to lymph nodes, and
frequently succumbed to their disease [6].
Our patient initially presented with disseminated
multiple mediastinal lymph-node plasmacytomas withoutbone-marrow involvement. The radiation therapy did not
produce a significant disease response; however, the
patient achieved an excellent disease control with combi-
nation chemotherapy with VTD-PACE. Whether radiation
therapy should be included as the treatment of mediastinal
lymph-node plasmacytoma remains unknown due to the
rarity of this particular pattern of disease manifestation.
Prior literature on solitary plasmacytoma suggested the
elevated light chain and a hypermetabolic lesion on a posi-
tron emission tomography scan as predictors of evolution
to myeloma, which were present in our case [10]. Once
a disease response is achieved with initial systemic ther-
apy, it appears reasonable to proceed with high-dose
chemotherapy followed by autologous HCT for consolida-
tion primarily based on the multiple-myeloma literature.
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toma treated with autologous HCT as intensification of
therapy has been described in the literature [11]. We also
initiated the patient on lenalidomide maintenance therapy
and so far there is objective evidence of complete
remission.
With regard to treatment outcomes of plasmacytomas in
general, Suh et al. [12] described an impressive objective
response rate of 100% (complete response of 82%) in a series
of 38 patients with solitary plasmacytomas (extramedullary
soft tissue [EMS] = 16 and solitary bone plasmacytoma [SBP]
= 22) treated with radiation therapy either alone or in com-
bination with chemotherapy and/or surgery. The Greek
myeloma study group described the outcomes of 97 patients
with solitary plasmacytomas (EMS = 32, SBP = 65) showing no
difference in 10-year overall survival in solitary plasmacy-
tomas (EMS = 89% vs. SBP = 69%, p = .2) [13]. Interestingly,
their analysis showed that the addition of conventional
chemotherapy or proteasome inhibitors/immunomodulatory
agents resulted in increased toxicity without adding
an apparent survival advantage over radiation therapy
alone [13].
In summary, our case illustrates the unique and rare pre-
sentation of primary lymph-node plasmacytomas involving
the mediastinum potentially mistaken as lymphoid malig-
nancy. Clinicians should be aware of the plasma-cell origin
of the mediastinal neoplastic process. When the disease
involves the mediastinum, it is unclear whether radiation
therapy has a significant role contrary to what is known in
lymphoid malignancy. Systemic therapy extrapolating from
the treatment strategy of multiple myeloma should be
strongly considered. Disseminated primary lymph node plas-
macytomas may be best consolidated with intensive high-
dose therapy followed by autologous HCT and subsequent
maintenance therapy.
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